PharmacoEconomics

Loss Aversion and Cost Effectiveness of Healthcare Programmes
pp. 895-898(4)
Author: Gandjour, Afschin

Loss Aversion and Cost Effectiveness of Healthcare Programmes: Whose Aversion Counts Anyway?
pp. 899-900(2)
Author: Severens, Johan L.

Methods for the Meta-Analysis of Willingness-to-Pay Data: An Overview
pp. 901-910(10)
Author: George Van Houtven,

The Impact of Influenza on Working Days Lost: A Review of the Literature
pp. 911-924(14)
Authors: Keech, Martin; Beardsworth, Paul

A Review of Health-Utility Data for Osteoarthritis: Implications for Clinical Trial-Based Evaluation
pp. 925-935(11)
Authors: Ruchlin, Hirsch S.; Insinga, Ralph P.

A Cost-Effectiveness Analysis of Currently Approved Treatments for HBeAg-Positive Chronic Hepatitis B
pp. 937-949(13)
Authors: Spackman, D. Eldon; Veenstra, David L.

Economic Impact and Long-Term Graft Outcomes of Mycophenolate Mofetil Dosage Modifications Following Gastrointestinal Complications in Renal Transplant Recipients
pp. 951-967(17)
Authors: Machnicki, Gerardo; Ricci, Jean-Francois; Brennan, Daniel C.; Schnitzler, Mark A.

Escitalopram and Duloxetine in Major Depressive Disorder: A Pharmacoeconomic Comparison Using UK Cost Data
pp. 969-981(13)
Authors: Wade, Alan G.; Fernández, José-Luis; François, Clément; Hansen, Karina; Danchenko, Natalya; Despiegel, Nicolas